WCG targets pain management, opioid alternatives in Analgesic Solutions deal

By Maggie Lynch

- Last updated on GMT

(Image: Getty/gradyreese)
(Image: Getty/gradyreese)
WCG acquires Analgesic Solutions for advisement on protocol design and the development of clinical trials in which pain is an indicator of an underlying condition.

The WIRB-Copernicus Group (WCG) Clinical Services Division acquired pain medications developer Analgesic Solutions to strengthen clinical trial processes and advance alternatives to opioids which are in great demand.

Robert Newman, CEO of Analgesic Solutions, said in a statement, “The quest to combat the misuse and abuse of pharmaceuticals and to uncover effective pain management alternatives has brought many new players to the space.”

However, trials for pain management alternatives have unique challenges that make the studies difficult to conduct, he explained.

According to Analgesic Solutions, because pain is a subjective experience, the company advises clinicians on how to better evaluate patients’ descriptions in clinical trials in which pain is an endpoint or significant component.

Analgesic Solutions will advise sponsors on protocol design and development, providing central statistical monitoring to proactively ensure accurate study outcomes. Analgesic Solutions also works with companies for submissions to the US Food and Drug Administration (FDA) and other regulatory organizations.

Per the acquisition, WCG gains access to Analgesic Solutions’ Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS), created in collaboration with the FDA-ACTTION​ initiative, for classifying and quantifying abuse-related events in clinical trials. The acquisition will see Analgesic Solutions gain access to capital, expertise and corporate operational support. The company will continue to operate independently at its headquarters in Wayland, MA. 

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars